Login with Linked

Follow us on

Link Linkedin Youtube

Voranigo

Voranigo is an oral treatment for adults and teens with Grade 2 astrocytoma or oligodendroglioma that carry an IDH1 or IDH2 mutation, used after surgery. It blocks mutant IDH enzymes to slow tumor progression, significantly extending the time before disease worsens

Molecule Details :

  • Molecule Name :

    Vorasidenib

  • Innovator :

    SERVIER PHARMACEUTICALS LLC

  • Approval Date :

    06-Aug-24

  • NCE-1 Date :

    06-Aug-28

  • NCE Date :

    06-Aug-29

  • Dosage Form :

    Oral Tablets

  • Strength :

    10 mg and 40 mg

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    102

  • 2026 :

    134

  • 2027 :

    156

  • 2028 :

    167

  • 2029 :

    173

  • 2030 :

    177

  • 2031 :

    183
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?